Clinical Trial Update: PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating perioperative treatment with COI-B (capecitabine, oxaliplatin, irinotecan, and bevacizumab) for high-risk or borderline resectable co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer with Liver Metastases

Drugs mentioned

• Bevacizumab (bevacizumab)
• COI-B
• Capecitabine (capecitabine)
• Irinotecan (Irinotecan)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Colorectal Cancer Liver Metastases | Phase 2 | Status: COMPLETED